Evaluating financial viability of clinical programs under prospective pricing

Area of Science:

• Health Services Research
• Hospital Financial Management
• Clinical Program Evaluation

Background:

• Prospective pricing, particularly Medicare's Diagnosis-Related Group (DRG) system, creates financial incentives for hospitals.
• Evaluating the financial viability of individual clinical programs is crucial for hospitals under these new payment models.

Purpose of the Study:

• To examine the implications of hospital product lines for financial evaluation.
• To assess the suitability of Diagnosis-Related Groups (DRGs) as definitions for hospital products.
• To propose criteria for effective product definitions and explore implementation challenges.

Main Methods:

• Analysis of the limitations of Diagnosis-Related Groups (DRGs) for defining hospital services.
• Development of criteria for useful product definitions in hospital financial analysis.
• Case study of an orthopedic service at a teaching hospital, comparing DRG-based and hospital-defined product line evaluations.

Main Results:

• Diagnosis-Related Groups (DRGs) are often poor definitions of services provided by individual hospitals.
• Hospital-specific product line definitions are necessary for accurate financial viability assessments.
• The case study demonstrated the practical application and benefits of using hospital-defined product lines.

Conclusions:

• Hospitals must develop their own product line definitions to effectively manage financial viability.
• Relying solely on Diagnosis-Related Groups (DRGs) can lead to inaccurate financial evaluations.
• Implementing hospital-specific product definitions is essential for strategic financial planning in healthcare.